Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 combinations in breast cancer
NCT05353361Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Hengrui. Started May 2022; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05353361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353361.